Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Shares Outstanding (Diluted Average) (2020 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $98.6 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 8.95% to $98.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $98.6 million through Dec 2025, up 8.95% year-over-year, with the annual reading at $98.6 million for FY2025, 8.95% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $98.6 million at Ultragenyx Pharmaceutical, down from $99.8 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $99.8 million in Q3 2025, with the low at $67.5 million in Q3 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $80.5 million, with a median of $72.6 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) grew 1.23% in 2023, then surged 33.25% in 2024.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $67.8 million in 2021, then grew by 3.13% to $69.9 million in 2022, then rose by 5.13% to $73.5 million in 2023, then rose by 23.13% to $90.5 million in 2024, then rose by 8.95% to $98.6 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $98.6 million, $99.8 million, and $97.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.